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Poly(N-(2-Hydroxypropyl) methacrylamide) (poly(HPMA)) is gaining pharmaceutical attention in replacement to 
PEG as a hydrophilic stabilizer for polymer nanoparticles (NPs) devoted to systemic administration.[1] This is 
due to its biocompatibility, prolonged circulation time and, compared to PEG, to the avoidance of allergic 
reactions and of the accelerated blood clearance effect.[2, 3] In this work, a lipophilic HPMA-based 
macromonomer with a predetermined and controllable structure is synthesized for the first time attaching a short 
oligo(caprolactone) chain obtained via Ring Opening Polymerization (ROP) to the HPMA using a succinic acid 
unit as a spacer. This biodegradable monomer (hereinafter HPMA-CL) was then used to synthesize well-defined 
amphiphilic block copolymers comprising a hydrophilic poly(HPMA) block and a hydrophobic poly(HPMA-CL) 
segment via Reversible Addition-Fragmentation Transfer (RAFT) polymerization. The combination of ROP and 
RAFT allows the production of a library of polymers with a predetermined and controlled structure that are able 
to self-assemble in water into biodegradable NPs with different size. In particular, such NPs are designed to 
degrade in aqueous environment into completely water soluble poly(HPMA), with a molecular weight that is 
below the critical threshold for the renal excretion. This is a very important feature since it allows to avoid 
polymer accumulation into the body once the NPs are injected.[4] The degradation time is a function of the 
number of caprolactone units in the HPMA-CL macromonomer and of its degree of polymerization in the NP 
forming copolymer. Then, the 
polymer structure can be adjusted 
to obtain the desired degradation 
time. Finally, the possibility for 
such nanoparticles to physically 
incorporate and mediate the 
release of a lipophilic 
antineoplastic drug was evaluated 
in the case of Trabectedin. The 
formulation proved to be 
biocompatible and to sustainedly 
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Figure 7 – poly(HPMA)-b-poly(HPMA-CL) are able to self-assemble in 
water into completely biodegradable NPs, designed to leave the water 
soluble poly(HPMA) once the degradation is completed. 
